Synergistic antitumor responses by combined GITR activation and sunitinib in metastatic renal cell carcinoma

A phase I study to evaluate safety and antitumor activity of biweekly BMS-936558 (Anti-PD-1, MDX-1106/ONO-4538) in patients with RCC and other advanced refractory malignancies.

(2017) D. F. McDermott et al.   JOURNAL OF CLINICAL ONCOLOGY

Monitoring T-cell responses in a phase II study of AGS-003, an autologous dendritic cell-based therapy in patients with newly diagnosed advanced stage renal cell carcinoma in combination with sunitinib.

(2017) R. A. Figlin et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises

(2015) F. Massari et al.   CANCER TREATMENT REVIEWS

Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice

(2014) J. T. Murphy et al.   BLOOD

Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study

(2014) Shailender Bhatia et al.   Journal for ImmunoTherapy of Cancer

Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells

(2013) I. Melero et al.   CLINICAL CANCER RESEARCH

Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination

(2013) I. Melero et al.   CLINICAL CANCER RESEARCH

Deciphering and Reversing Tumor Immune Suppression

(2013) Greg T. Motz et al.   IMMUNITY

Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy

(2013) Ritika Jaini et al.   INTERNATIONAL JOURNAL OF CANCER

Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor

(2013) Matteo Santoni et al.   INTERNATIONAL JOURNAL OF CANCER

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

(2013) Yannick Bulliard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Advances in targeting cell surface signalling molecules for immune modulation

(2013) Sheng Yao et al.   NATURE REVIEWS DRUG DISCOVERY

Emerging immunotherapies for renal cell carcinoma

(2012) B. Escudier   ANNALS OF ONCOLOGY

Targeted therapeutic strategies for the management of renal cell carcinoma

(2012) Eric A. Singer et al.   CURRENT OPINION IN ONCOLOGY

Novel Therapies for Metastatic Renal Cell Carcinoma: Efforts to Expand beyond the VEGF/mTOR Signaling Paradigm

(2012) S. K. Pal et al.   MOLECULAR CANCER THERAPEUTICS

Adjuvant therapy for locally advanced renal cell cancer: A systematic review with meta-analysis

(2011) Adolfo JO Scherr et al.   BMC CANCER

Pharmacological modulation of GITRL/GITR system: therapeutic perspectives

(2011) Giuseppe Nocentini et al.   BRITISH JOURNAL OF PHARMACOLOGY

mTOR Kinase Inhibitor AZD8055 Enhances the Immunotherapeutic Activity of an Agonist CD40 Antibody in Cancer Treatment

(2011) Q. Jiang et al.   CANCER RESEARCH

Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma

(2010) Brian I. Rini et al.   CANCER

Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy

(2010) David Coe et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Direct and Differential Suppression of Myeloid-Derived Suppressor Cell Subsets by Sunitinib Is Compartmentally Constrained

(2010) Jennifer S. Ko et al.   CANCER RESEARCH

Macrophages, innate immunity and cancer: balance, tolerance, and diversity

(2010) Alberto Mantovani et al.   CURRENT OPINION IN IMMUNOLOGY

The multikinase inhibitor Sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE2 in murine macrophages

(2010) Justin P. Edwards et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination

(2010) Anamika Bose et al.   INTERNATIONAL JOURNAL OF CANCER

Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy

(2010) Jonathan M. Weiss et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies

(2009) J. Ozao-Choy et al.   CANCER RESEARCH

Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells

(2009) H. Xin et al.   CANCER RESEARCH

Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients

(2009) J. S. Ko et al.   CLINICAL CANCER RESEARCH

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

(2008) M. M. Hipp et al.   BLOOD

High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma

(2008) Jacob A. Klapper et al.   CANCER

Abrogation of TGFβ Signaling in Mammary Carcinomas Recruits Gr-1+CD11b+ Myeloid Cells that Promote Metastasis

(2008) Li Yang et al.   CANCER CELL

Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review

(2008) Kiran Gupta et al.   CANCER TREATMENT REVIEWS

Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients

(2008) J. H. Finke et al.   CLINICAL CANCER RESEARCH